Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt Sells 10,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 10,000 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at $526,119.70. The trade was a 43.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Amy Bachrodt also recently made the following trade(s):

• On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total transaction of $200,400.00.

Maze Therapeutics Price Performance

Shares of MAZE traded up $1.38 during trading hours on Wednesday, hitting $41.43. The stock had a trading volume of 394,842 shares, compared to its average volume of 325,768. The firm has a 50 day simple moving average of $36.34 and a 200-day simple moving average of $24.46. The firm has a market capitalization of $1.99 billion and a P/E ratio of -1.98. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Analyst Ratings Changes

A number of analysts have commented on MAZE shares. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. BTIG Research boosted their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Wells Fargo & Company initiated coverage on Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $43.38.

Institutional Trading of Maze Therapeutics

A number of large investors have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. bought a new stake in shares of Maze Therapeutics in the first quarter valued at $45,460,000. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics in the 1st quarter worth about $45,362,000. Woodline Partners LP purchased a new stake in Maze Therapeutics in the 1st quarter worth about $10,229,000. Vanguard Group Inc. raised its stake in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the period. Finally, Marshall Wace LLP raised its stake in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.